



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Leminoprazole

Cat. No.:	HY-105094
CAS No.:	104340-86-5
Molecular Formula:	C ₁₉ H ₂₃ N ₃ OS
Molecular Weight:	341.47
Target:	Na ⁺ /K ⁺ ATPase
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Leminoprazole (NC 130003) is an inhibitor for acid pump, H ⁺ K ⁺ -ATPase,. Leminoprazole stimulates the secretion and synthesis of gastric mucus, attenuates gastric ulcers. Leminoprazole is orally active ^{[1][2][3]} .								
In Vitro	Leminoprazole inhibits H ⁺ ,K ⁺ -ATPase in rabbit gastric vesicle irreversibly through formation of covalent disulfide bond, with IC ₅₀ of 5.3 and 19 μM ^[1] . Leminoprazole inhibits histamine, carbachol, gastrin and db-cAMP-stimulated acid secretion, with IC ₅₀ s of 0.4, 0.35, 0.25 and 0.56 μM, respectively ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Leminoprazole (10-90 mg/kg, po, single dose) promotes the synthesis of gastric mucus, inhibits gastric acid secretion in Donyru rats model ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Donyru rats model^[3]</td> </tr> <tr> <td>Dosage:</td> <td>10-90 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>p.o., single dose</td> </tr> <tr> <td>Result:</td> <td>Increased levels of glucosamine, decreased acid secretion.</td> </tr> </table>	Animal Model:	Donyru rats model ^[3]	Dosage:	10-90 mg/kg	Administration:	p.o., single dose	Result:	Increased levels of glucosamine, decreased acid secretion.
Animal Model:	Donyru rats model ^[3]								
Dosage:	10-90 mg/kg								
Administration:	p.o., single dose								
Result:	Increased levels of glucosamine, decreased acid secretion.								

REFERENCES

- [1]. Masuda M, et al., [Studies on the inhibitory action of leminoprazole against rabbit gastric H⁺,K⁺-ATPase]. Nihon Yakurigaku Zasshi. 1994 Oct;104(4):325-35. Japanese.
- [2]. Saito E, et al., Inhibitory effect of leminoprazole on acid secretion in parietal cells isolated from guinea pig gastric mucosa. Jpn J Pharmacol. 1995 May;68(1):19-23.
- [3]. Takahashi S, et al., Mechanism by which orally administered leminoprazole stimulates mucus synthesis in rats. Pharmacology. 1998 Jul;57(1):47-56.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA